ATS 2020 Advance Program

TRANSLATIONAL POSTGRADUATE COURSE PG26 JUMP START: A BEGINNER’S GUIDE TO DRUG AND COMPANY DEVELOPMENT AND IN AN ACADEMIC SETTING Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited. Member: $400 In-Training Member: $250 Non-Member: $475 In-Training Non-Member: $350 Assembly on Respiratory Cell and Molecular Biology; Drug Device Discovery and Development Committee 8:00 a.m. - 4:00 p.m. Target Audience Investigators pursuing basic and translational or clinical who are interested in entrepreneurship and forming a NewCo at University. Objectives At the conclusion of this session, the participant will be able to: • understand drug development within academic setting with an entrepreneurial approach; • learn about essentials in intellectual property (patents), target engagement, pre-IND enabling and clinical study design; • understand challenges with business-related grant proposals and importance in working with Venture Capitalists to build the NewCo at University. Design a presentation to investors and integrate business related thinking into an academic project. This course will show the best practices to develop a new drug and form a company from a discovery made in an academic lab. Innovative thinking and cutting-edge research in medicine shows promise to translate key discoveries into novel drugs. However, many researchers and clinicians are not familiar with the best practices when developing novel drugs in academia. Here, attendees will discover real-life examples about building a NewCo at a University with particular focus on lung diseases relevant to the ATS. This course will focus on how to decide if an idea is ready for commercialization, approaches to strengthen Intellectual Property (patents) and what is required to enable application for an IND. The session will also discuss business grant proposals and work with Venture Capitalists (VCs) to raise funds. Chairing: M. Vukmirovic, PhD, New Haven, CT K.H. Benam, PhD, Aurora, CO S.V. Raju, BPharm, PhD, Birmingham, AL T.M. Maher, MD, MSc, PhD, London, United Kingdom 8:00 Introduction and General Welcome M. Vukmirovic, PhD, New Haven, CT 8:10 An Introduction to Drug Development in Lung Diseases - Academic Perspective D. Sheppard, MD, San Francisco, CA 8:35 What’s Mine Is Mine: Promoting and Protecting Your IP After Publication N.J. Kenyon, MD, MSCR, Sacramento, CA 9:00 The Importance of Target Engagement Studies in Preclinical Research L. Murray, PhD, Cambridge, United Kingdom 9:25 Questions and Answers 9:40 Break 9:50 Expert Fireside Chats: The Future of Pulmonary Medicine S. Hobbie, Biberach, Germany J.G. Garcia, MD, Tucson, AZ 10:20 Panel Discussion: Taking the Next Steps After Discovery R. Tarran, PhD, Chapel Hill, NC A.H. Cohen, MD, Menlo Park, CA M. Vukmirovic, PhD, New Haven, CT 11:05 Introduction to Pre-IND Enabling Studies and Clinical Trials T.M. Maher, MD, MSc, PhD, London, United Kingdom 11:30 Power Lunch: Navigating and Growing an Academic Startup J.J. Rose, MD, MBA, Pittsburgh, PA R.K. Mallampalli, MD, Columbus, OH ATS 2020 • Philadelphia, PA SATURDAY • MAY 16 31